Study Summary
This trial will test a new drug, BIO89-100, to see if it is safe and effective in treating patients with a certain kind of liver disease.
- Non-alcoholic Fatty Liver Disease (NAFLD)
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
4 Primary · 19 Secondary · Reporting Duration: 12 Weeks, 24 Weeks, 48 Weeks
Trial Safety
Phase-Based Safety
Trial Design
5 Treatment Groups
BIO89-100 - 15 mg QW
1 of 5
Experimental: BIO89-100 - 44 mg Q2W
1 of 5
Experimental: BIO89-100 - 30 mg QW
1 of 5
Placebo Comparator: Placebo QW
1 of 5
Placebo Comparator: Placebo Q2W
1 of 5
Experimental Treatment
Non-Treatment Group
216 Total Participants · 5 Treatment Groups
Primary Treatment: BIO89-100 · Has Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 21 - 75 · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
Georgia | 50.0% |
New York | 50.0% |
How old are they?
18 - 65 | 100.0% |
What site did they apply to?
89bio Clinical Study Site | 100.0% |
What portion of applicants met pre-screening criteria?
Met criteria | 50.0% |
Did not meet criteria | 50.0% |
Why did patients apply to this trial?
- "I want to know what's wrong with me!"
What questions have other patients asked about this trial?
- "How long is the study?"
How many prior treatments have patients received?
0 | 100.0% |
Frequently Asked Questions
Who would be eligible to partake in this medical trial?
"This clinical trial is seeking 216 individuals between the ages of 21 and 75 who have been biopsy-confirmed to possess nonalcoholic steatohepatitis with fibrosis stage F2 or F3 according to NASH CRN System classification. Each patient must also display a score of 1 in each category (steatosis, ballooning degeneration, and lobular inflammation) on their qualifying biopsy - which should be conducted within 6 months prior to screening visit or during the screening period itself." - Anonymous Online Contributor
What potential risks could arise from using BIO89-100?
"Our team at Power assigned BIO89-100 a safety rating of 2, as while it has been tested in preclinical trials and demonstrated its security, there is no evidence yet to back up the efficacy of this medication." - Anonymous Online Contributor
Are individuals currently being accepted into this clinical experiment?
"The clinicaltrials.gov website reveals that this particular medical trial is not currenlty looking for new participants, as the last update to it was on September 5th 2022. Despite this study's inactivity, there are 233 other trials presently recruiting volunteers." - Anonymous Online Contributor
Is eligibility for this experiment restricted to those aged 30 and over?
"To be considered for this trial, patients must have an age between 21 and 75. Those below 18 or above 65 can look into the 22 trials dedicated to minors or 191 studies focusing on seniors respectively." - Anonymous Online Contributor
How many medical facilities are participating in this research endeavor?
"At present, 72 medical centres across the country are recruiting participants for this trial. San Diego, Huntington Beach and Westlake represent some of these sites; however there are many more locales where enrolment is possible. To make participation more comfortable, it would be prudent to select a clinic in close proximity to reduce required travel time." - Anonymous Online Contributor